Abstract
A solution of the present invention useful for flushing an intravascular
catheter includes a pharmacologically acceptable solium salt, a pharmacologically
acceptable calcium salt, a pharmacologically acceptable potassium
salt and about one milligram per milliliter polyhexamethylene biguanide
hydrochloride in an aqueous admixture. Additionally, the solution
of the invention may also contain a pharmacologically acceptable salt
of lactic acid.
Claims
What is claimed is:
1. A method for flushing an intravascular catheter comprises: providing
a solution substantially free of viable microorganisms comprising
an admixture of between about 820 mg to about 900 mg sodium chloride,
between about 28.5 mg to about 31.5 mg potassium chloride, between
about 30.0 to about 36.0 mg calcium chloride as the dihydrate and
about one hundred milligrams polyhexamethylene biguanide in one
hundred milliliters of water for injection U.S.P; filling a fluid
handling device with an aliquot of said solution; attaching the
fluid handling device having said aliquot of said solution therein
to a patient's intravascular catheter that requires flushing; and
administering said solution into the catheter, thereby flushing
the catheter.
2. The method of claim 1 wherein said filling step comprises filling
the fluid handling device with between about two and about three
milliliters of said solution.
3. The method of claim 1 wherein said administering step is practiced
on a patient at intervals sufficient to maintain patency of the
catheter.
4. The method of claim 1 wherein said providing step further comprises
providing sodium lactate in a concentration between about 290 mg
and about 330 mg in said one hundred milliliters of water for injection
U.S.P.
5. The method of claim 1 wherein said fluid handling device comprises
a syringe.
Description
FIELD OF THE INVENTION
[0001] The present invention is generally related to intravascular
catheters and more particularly to a solution useful for maintaining
the patency of a long-term indwelling intravascular catheter and
a method for its use.
BACKGROUND
[0002] Intravascular catheters are among the most commonly used
medical devices. Such catheters are routinely placed into a patient's
vascular system for many procedures and often are left in place
for extended periods. Since an intravascular catheter is a direct
path from the outside environment to the patient's bloodstream,
the catheter's presence presents a substantial and continuous potential
for introduction of microorganisms into the patient's bloodstream.
Practitioners have developed many protocols related to placement,
use, attachment and detachment of fluid handling devices and other
procedures related to catheters. The goal of almost all of these
procedures is to avoid introduction of a microorganism into the
patient's bloodstream. When a medicament is introduced into a patient
through a catheter, the practitioner commonly follows the introduction
with a flush solution that may include an anticoagulant such as
heparin. The purpose of the flush solution is to move the medicament
out of the catheter so that the entire dosage is delivered, and
to leave a residual fill in the catheter so that the patient's blood
does not back up in the catheter and possibly form a clot that would
occlude the bore of the catheter. Thus, when the catheter is subsequently
needed again, the properly flushed catheter is likely fully patent
and ready for the next usage.
[0003] In 1988, Root, et al., published a study that reported on
the effect of disodium ethylene diamine tetra acetic acid (EDTA),
a compound well known for its chelating properties in vivo and widely
used as an anticoagulant in vitro. The authors compared EDTA, heparin
and vancomycin/heparin for effectiveness upon the growth of S. epidermis
in vitro and its relation to infection prophylaxis of Hickman catheters
in their report in Antimicrob. Agents Chemother., 32:1627-1631,
1988. Recently, Raad, et al. in U.S. Pat. No. 5,363,754 disclosed
that pharmaceutical compositions of a mixture of minocycline and
EDTA were useful in maintaining the patency of a catheter port.
More recently, Raad, et al. in U.S. Pat. No. 5,688,516 further disclosed
that effective catheter flush solutions could be prepared with non-glycopeptide
antimicrobial agents other than vancomycin and a second agent selected
form the group consisting of: (a) an anticoagulant, (b) an antithrombotic
agent and (c) a chelating agent selected from a group of chelating
agents. Raad, et al. teaches that since many antibiotic agents are
not particularly stable at ambient conditions in aqueous solutions,
that the disclosed compositions are stable and effective for about
one month when stored under refrigerated conditions and that the
solution should be brought to room temperature before administration
to a patient. Alternatively, Raad, et al. teaches a kit including
three compartments, the compartments containing the antimicrobial
agent, the chelating, anticoagulant or antithrombotic agent and
a diluent such as saline, Ringers solution or water so that the
practitioner could mix the components prior to administration to
the patient, thereby avoiding the reported stability problems.
[0004] While the disclosures of Raad, et al. teach a series of
antimicrobial agents with a variety of other compounds, given the
tendency of microorganisms to develop resistance to many antibiotic
agents and the sensitivity to many people to certain antibiotics
and other compounds, there still is a need for a catheter flush
solution that does not include an antibiotic, is stable under ambient
storage conditions and contains only materials with little likelihood
of inducing an allergic response in a sensitive patient. Such a
solution is disclosed hereinbelow.
SUMMARY
[0005] A solution of the present invention useful for flushing
an intravascular catheter includes a pharmacologically acceptable
sodium salt, a pharmacologically acceptable calcium salt, a pharmacologically
acceptable potassium salt and about one milligram per milliliter
polyhexamethylene biguanide hydrochloride in an aqueous admixture.
Additionally, the solution of the invention may also contain a pharmacologically
acceptable salt of lactic acid.
[0006] The catheter flush solution of the invention, when compared
under in vitro simulated use conditions to a known catheter flush
solution composed of minocycline and ethylenediaamine tetra acetic
acid (M-EDTA), suprisingly showed similar results in activity against
microorganisms in established biofilms. Additionally, unlike the
M-EDTA, which is stable for about one month under refrigeration,
the catheter flush solution of the invention retains full activity
even after autoclave sterilization or ultra filtration. The catheter
flush solution of the invention is simple to prepare, is thermally
stable and has acceptable toxicity properties consistent with its
intended use.
DETAILED DESCRIPTION
[0007] While this invention is satisfied by embodiments in many
different forms, herein described in detail preferred embodiments
of the invention with the understanding that the present disclosure
is to be considered exemplary of the principles of the invention
and is not intended to limit the invention to the embodiments described.
[0008] A solution of the present invention useful for flushing
an intravascular catheter includes a pharmacologically acceptable
sodium salt such as sodium chloride or the like in a concentration
of between about 820 mg to about 900 mg, a pharmacologically acceptable
calcium salt, such as calcium chloride dihydrate or the like in
a concentration between about 30.0 mg to about 36.0 mg, a pharmacologically
acceptable potassium salt, such as potassium chloride or the like
in a concentration between about 28.5 to about 31.5 mg and about
one milligram per milliliter polyhexamethylene biguanide hydrochloride
in an aqueous admixture with one hundred milliliters of water for
injection U.S.P. For particular applications, the solution of the
invention may also include sodium lactate in a concentration between
about 290 mg and about 330 mg in the one hundred milliliter aqueous
admixture.
[0009] The solution of the invention is preferably exposed to conditions
that substantially render any microorganisms therein non-viable
and packaged in a sealed vessel, such as a syringe, septum-closed
vial or an ampoule that is substantially resistant to the passage
of microorganisms. Preferably, the sealed vessel contains an aliquot
of the flush solution that is sufficient to perform one catheter
flush procedure. For particular applications, a bulk vessel may
be preferred that contains a sufficient amount of the solution to
dispense multiple aliquots for individual catheter flush procedures.
[0010] An in vitro comparison between the catheter flush solution
containing sodium lactate of the invention and a catheter flush
solution disclosed in U.S. Pat. No. 5,362,754 including minocycline
and ethylene diaamine tetraacetic acid (M-EDTA) was conducted. The
results of this evaluation of the two solutions' activity on tubing
that had P. aeruginosa in established biofilms suprisingly showed
that the catheter flush solution of the invention performed similarly
to the M-EDTA solution disclosed in U.S. Pat. No. 5,362,754. Table
I lists the variables used in the comparison and the results. In
this comparison, segments of test tubing were incubated in trypticase
soy broth (TSB) containing P. aeruginosa to acquire a loading in
the tubing bore of the biofilm containing the microorganism. The
tubing segments were recovered from the broth and attached to syringes
containing the catheter flush solutions. The test solutions were
injected into the tubing segments with the syringe and allowed to
stand at ambient conditions. At the times indicated, the solutions
were withdrawn from the particular segments of tubing, the tubing
bore washed with sterile saline and the saline was cultured providing
the results in the table. In this comparison, the flush solution
of the invention included sodium lactate in the concentration as
described above.
1TABLE I Colony forming units (CFU) Time elapsed recovered/cm.sup.2
of (hours) Tubing Material Test solution tubing 0 Silicone None
(control) >9,500 0 Polyvinylchloride None (control) >15,000
3 Silicone 5,362,754 >9,500 3 Silicone Invention >9,500 3
Polyvinylchloride 5,362,754 <15 3 Polyvinylchloride Invention
<15 5 Silicone 5,362,754 <9.5 5 Silicone Invention 9,500 5
Polyvinylchloride 5,362,754 <15 5 Polyvinylchloride Invention
<15 24 Silicone 5,362,754 13 24 Silicone Invention 9.5 24 Polyvinylchloride
5,362,754 <15 24 Polyvinylchloride Invention <15
[0011] Established biofilms are difficult to eradicate and the
bacteria established in these films are resistant to conventional
antibiotic treatment. The flush solution of U.S. Pat. No. 5,362,754
has been shown to be effective in preventing device related infections
partially or completely due to its effect on biofilms and the bacteria
in these films.
[0012] Additionally, a comparison of the minimum inhibitory concentration
(MIC) of the solution of the invention after filter sterilization
and after steam sterilization following a widely accepted protocol
in an autoclave. The flush solutions of the invention showed no
difference in the MIC between the filter sterilized by passage of
the solution through a 0.22 micron filter and the steam sterilized
solution of the invention against S. aureus, P. aeruginosa, E. Coli
and C. albicans. The stability of the flush solution to steam sterilization
suggests that the long term shelf stability at ambient temperatures
of prepackaged unit dose aliquots of the solution should be at least
two years, although this is yet to be confirmed.
[0013] A method for flushing an intravenous catheter includes providing
an admixed solution substantially free of microorganisms containing
between about 820 mg to about 900 mg of sodium chloride, between
about 28.5 to about 31.5 mg of potassium chloride, between about
30.0 to about 36.0 calcium chloride dihydrate, about 100 mg polyhexamethylene
biguanide hydrochloride in one hundred milliters of water for injection
U.S.P. The solution of the invention preferably includes between
about 290 mg to about 330 mg of sodium lactate. The method includes
filling a fluid handling device, preferably a syringe, with an aliquot
of the solution sufficient to perform a catheter flush procedure.
The preferred amount for the flush procedure is generally about
two or three milliliters. The practitioner then attaches the syringe
to the target intravascular catheter that requires flushing and
administers the solution into the catheter, thereby completing the
flush procedure. The frequency of the performance of the procedure
may be once daily or, for particular situations, more or less frequently.
[0014] Toxicity studies of the preferred catheter flush solution
of the invention containing sodium lactate show that at doses of
the polyhexamethylene biguanide hydrochloride at up to one time,
ten times, fifty times and seventy times the expected dose level
(two ml flush in a seventy kg. Human) level, there was no significantly
greater biological reactivity compared to controls. Toxicity studies
of the preferred catheter flush solution at eighty five times (lowest
observable acute effect level), one hundred times, and two hundred
times the expected dose level, there was slight to moderate biological
reactivity compared to controls. At a dosage level of one thousand
times the expected dosage level, there was significantly greater
reactivity compared to controls.
[0015] The pharmacologically acceptable salts used in the preparation
of the flush solution of the invention, i.e. sodium chloride, calcium
chloride dihydrate, potassium chloride and sodium lactate are widely
available. Any source of these materials meeting the requirements
of the United States Pharmacopeia (U.S.P.) are satisfactory. The
same is true for the water for injection U.S.P. Any water that meets
the requirements listed in the U.S.P. for water for injection is
satisfactory for use in the invention.
[0016] Polyhexamethylene biguanide hydrochloride with a molecular
formula of C.sub.8H.sub.18N.sub.5Cl(C.sub.8H.sub.18N.sub.5Cl).sub.n
is a polymeric material with a molecular weight between about 1800
and about 2400 and is available as a twenty percent aqueous solution
from Zeneca, Wilmington, Del. as Cosmocil.RTM. CQ. The compound
has high activity against a wide range of microorganisms, it has
very low mammalian toxicity and is chemically stable. The compound
is widely used as a preservative in cleaning solutions for contact
lenses. Polyhexamethylene biguanide hydrochloride is also referred
to as polyaminopropyl biguanide by the Cosmetic Toiletries and Fragrances
Association (CTFA) who recognize its use as a preservative in water
in oil and oil in water emulsions and as a antimicrobial agent in
surgical scrubs.
[0017] The pharmacologically acceptable salts and the water for
injection U.S.P. portion of the solution of the invention substantially
corresponds to the U.S.P. formulation for Ringer's solution and
Lactated Ringer's solution. This portion is well recognized as a
benign vehicle for intravenous infusion. The addition of the polyhexamethylene
biguanide hydrochloride at the level disclosed herein suprisingly
renders the solution substantially as capable of eliminating microorganisms
present in established biofilms as the combination of the M-EDTA
of the art. Unlike the previous catheter flush solution of the art,
the catheter flush solution of the invention exhibits good thermal
stability, a property that makes it suitable for packaging in ready-to-use
unit dose kits capable of being stored at ambient conditions. |